vTv Therapeutics up after FDA lifts clinical hold on its oral diabetes treatment study
Tv Therapeutics (NASDAQ:VTVT) said on Monday that the U.S. FDA has lifted the clinical hold on cadisegliatin's clinical trial ...
FDA approves Xeris Biopharma’s sNDA of Gvoke VialDx as gastro diagnostic aid
Holdings announced that its supplemental new drug application, sNDA, of Gvoke VialDx has received U.S Food and Drug ...
vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes
Cadisegliatin has the potential to be the first oral adjunct therapy for type 1 diabetesCATT1 Phase 3 trial expected to resume following ...
VTv Therapeutics Shares Rise After FDA Lifts Hold on Diabetes Treatment
Shares of vTv Therapeutics rose after the Food and Drug Administration lifted a clinical hold on its diabetes treatment program. The stock gained 40% to $20.78 Monday morning. Shares have climbed ...
Sequana Medical NV: Press release: Sequana Medical announces 2024 Full Year Results and 2025 Outlook
Sequana Medical announces 2024 Full Year Results and 2025 Outlook alfapump® - US FDA approval of alfapump® for the treatment of recurrent or refractory ascites due to liver cirrhosis; US commercial ...
Genmab A/S: Investigational Rinatabart Sesutecan (Rina-S) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer
Media ReleaseCOPENHAGEN, Denmark; March 17, 2025 Results from Phase 2 RAINFOLTM-01 trial (B1 cohort) showed that with a median on-study follow-up of 48 weeks, Rina-S 120 mg/m2 led to a confirmed objec ...